Efficacy of bronchial arterial infusion of paclitaxel combined with systemic chemotherapy for patients with advanced non-small cell cancer
- VernacularTitle:支气管动脉灌注紫杉醇联合全身化疗治疗晚期非小细胞肺癌
- Author:
Hua ZHANG
;
Pengfei LUO
;
Liangmin ZHANG
- Publication Type:Journal Article
- Keywords:
Bronchial arterial infusion;
Paclitaxel;
Non small cell lung cancer
- From:
Journal of Interventional Radiology
2001;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and toxicity of bronchial arterial infusion (BAI) combined with systemic administration of paclitaxel (Taxol) in the treatment of patients with advanced non small cell cancer (NSCLC).Methods Fifty seven patients with NSCLC were received paclitaxel and carboplatin through the bronchial artery and follow by systemic administration of paclitaxel for 2～3 cycles. The positive response and adverse effects were assessed. Results In 57 patients, complete response (CR) were obtained in 6 and partial response (PR) in 28 cases, with overall response rate (RR) of 59.6%. The main toxicity included mild myelosuppression, gastrointestinal effects, and alopecia.Conclusions The combination of BAI of paclitaxel and systemic chemotherapy is highly effective for advanced NSCLC, and causes mild adverse effects.
